Huang, Hai <br/><br/>
Baicalin benefits the anti-HBV therapy via inhibiting HBV viral RNAs.  [electronic resource] 

 -  Toxicology and applied pharmacology  05 2017 
 - 36-43 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1096-0333 
<br/><br/><label>Standard No.: </label>10.1016/j.taap.2017.03.016  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Animals, Newborn<br/>Antiviral Agents--pharmacology<br/>Biomarkers--blood<br/>DNA, Viral--genetics<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Drug Resistance, Viral<br/>Drug Therapy, Combination<br/>Ducks<br/>Flavonoids--pharmacology<br/>Guanine--analogs & derivatives<br/>Hep G2 Cells<br/>Hepatitis B Surface Antigens--blood<br/>Hepatitis B e Antigens--blood<br/>Hepatitis B virus--drug effects<br/>Hepatitis B, Chronic--diagnosis<br/>Hepatocyte Nuclear Factor 1-alpha--genetics<br/>Hepatocyte Nuclear Factor 4--genetics<br/>Host-Pathogen Interactions<br/>Humans<br/>RNA, Viral--biosynthesis<br/>Time Factors<br/>Transcription, Genetic--drug effects<br/>Transfection<br/>Viral Load